CCL4 and myeloid sarcoma: While still on injectable treatment (IFN-beta or GA), the median levels of IP-10 (CXCL10), IL-12/23p40, sVCAM-1, IL-8 (CXCL8), MIP-1β (CCL4), CRP, IL-15, sICAM-1 and SAA were significantly higher for MS patients compared with HC.